Classification of Tremors. Tremor& Ac,on& Tremor& Isometric& Tremor& Rest&tremor& Parkinson s* disease* Kine,c& tremor& Task5specific& tremor&
|
|
- Posy Cole
- 5 years ago
- Views:
Transcription
1 Common Movement Disorders in the Elderly David F. Tang-Wai MDCM FRCPC Assistant Professor (Neurology and Geriatric Medicine), University of Toronto 2013 UHN-MSH Geriatrics Update -- Friday November 1, 2013 Movement Disorders in the Elderly 1 The top 5 movement disorders in the elderly (Tse W et al. Arch Gerontol Geriatr 2008; 46: ) 1. Essential 2. Parkinson s disease* 3. Drug-induced tremor 4. Dystonia 5. Myoclonus * Discussed below TREMOR Definition: a rhythmic, involuntary, oscillating movements of reciprocally innervated agonist and antagonist muscles Classification of Tremors Tremor& Rest&tremor& Ac,on& Tremor& Isometric& Tremor& Parkinson s* disease* Postural& Kine,c& tremor& Task5specific& tremor& Physiologic* Cerebellar* Essen7al* Simple*kine7c* Midbrain* (Holmes)* Cerebellar* Essen7al* Wri7ng* see following page for definitions
2 Movement Disorders in the Elderly 2 Specific Tremor Syndromes Tremor Type Description Frequency Sample Disorders Action tremor Tremor present with movement (voluntary contraction of skeletal muscle) Cerebellar tremor Terminal/intention tremor Essential tremor Holmes Tremor/ Midbrain tremor/ Rubral tremor Kinetic tremor Isometric tremor Postural tremor Physiologic tremor Rest tremor Tremor prominent with voluntary movements in conjunction with cerebellar signs Usually affects proximal muscles, tremor is accentuated as the moving limb nears the target Increased amplitude during pursuit of a target Due to lack of feedback of the cerebellum to motor cortex and involvement of the dentatorubrothalamic pathway Postural or action-involved tremor that is, by definition, not present at rest Commonly affects the upper extremities (90%), head (50%) & voice (30%), legs & chin (15%) Suppression of tremor with EtOH Combination of rest, postural and kinetic tremor of the extremities Caused by interruptions in the midbrain tegmentum (lesions involving the thalamus, brain stem or cerebellum) tremor that appears during movement of a body part. Simple kinetic tremor can be brought out by the clinician by asking the subject to carry out simple rotary movements of the forearm, or moving the wrists up and down. Tremor evoked by voluntary muscle contractions without movement Tremor seen when a limb in maintained against gravity. Low amplitude tremor that is most prominent in outstretched hands Present in all individuals under certain circumstances Exacerbated by excited mental states, metabolic derangements, drugs, alcohol withdrawal, caffeine Tremor occurs when the limb is in a position of repose (body part is completely supported against gravity) Classically pronation-supination of forearm or pill-rolling movement of thumb and fingers 3-5 Hz Mass lesion Demyelinating disease Toxic Ischemic Infectious 4-12 Hz 2-4 Hz stroke trauma multiple sclerosis 8-12 Hz Mental state (e.g. anxiety, stress, fatigue) Metabolic (e.g. thyrotoxicosis, hypoglycemia, fever, pheochromocytoma) Drug-induced (e.g. β-adrenergic agonists, TCA, AEDs, lithium, thyroxine, steroids, neuroleptics) Toxins (e.g. heavy metals, alcohol withdrawal Diet (e.g. caffeine) 3-7 Hz Idiopathic Parkinson s disease Parkinsonism Drug-induced Wilson s disease Other Severe essential tremor
3 Examining tremor: Movement Disorders in the Elderly 3 Instructions Figure 1. Observe the patient at rest for a resting tremor. Can observe a resting tremor in the mouth, chin, forearm, fingers. Can enhance a resting tremor by cognitive distraction (e.g. saying the months of the year backwards; while walking, observe a pill-rolling tremor). 2. With the arms elevated and outstretched in front of the patient, can observe a postural tremor. Legs must be outstretched to reveal postural leg tremor. 3. With the head erect, can observe a head tremor: either a yes-yes tremor (back-and-forth oscillation) or no-no (side-to-side oscillation). 4. Asking the patient to hold a prolonged vowel sound (e.g. ahhh ) reveals a voice tremor. 5. Asking the patient to write or drinking a cup of water with one hand may elicit a tremor (essential and/or task-specific tremor). 6. Cerebellar tremors are elicited by target-directed actions finger-tonose or heel-to-shin. Oscillations increase as the finger approaches the target.
4 Rest & Essential Essential Tremor: Differentiating Essential Tremor from Parkinsonian Tremor Essential Tremor Movement Disorders in the Elderly 4 Rest Tremor (Parkinson s disease) Affects: Frequency Family History: Postural Component: Kinetic Component: Age Effects of alcohol Tremor Onset Muscle Tone Facial expression Gait Upper extremities (95%) Head (34%) - no-no > yes-yes Legs (20%) Voice (12%) Face (5%) There can be gradual somatotopic spread of tremor (ie: starts in arm and spread to head - converse is rare) Head: 2-8 Hz Arms: 4-12 Hz Elderly: Frequently can be slower & can be confused with tremor in PD Positive Essential tremor has both a postural & kinetic component. Patient asked to hold a body part motionless against the force of gravity Examples: Extending the upper limbs horizontally Protruding the tongue Patient asked to to perform a voluntary movement Examples (drinking from a cup, finger-to-nose, writing) Can worsen over years All age groups Reduces tremor Bilateral Normal Normal Normal pill-rolling action of the hands chin lips legs trunk Movement starts in one limb or on one side of the body and usually progresses to include the other side. Can be markedly increased by stress or emotions 4 Hz Usually negative Usually absent More than 25 percent of patients with Parkinson s disease have an associated action tremor. Usually over 60 years old Usually not beneficial Unilateral Rigidity ± cogwheeling Hypomimia/masked facies/decreased eye-blink Decreased arm swing, stooped, decreased stride length
5 Movement Disorders in the Elderly 5 Treatment Options for Essential Tremor (Chen JJ & Lee KC. Consultant Pharmacologist 2006; 21: 58-71; Louis ED. Clin Geriatr Med. 2006; 22: ; Thanvi B, Lo N, & Robinson T. Age & Ageing 2006; 35: ; Zesiewicz T et al; Neurology 2011; Treatment Mechanism of Action Usual Starting Dose Usual Therapeutic Dose Side Effects AAN Practice Guidelines Propanolol Beta-blocker 10 mg/day mg/day as BID dosing Fatigue, bradycardia, hypotension, depression, exercise intolerance Level A evidence Primidone Metabolized to phenobarbital 62.5 mg/day mg/day as QHS to BID dosing Sedation, nausea, vomiting, unsteadiness/ataxia Level A evidence Gabapentin Similar to GABA inhibitory neurotransmitter 300 mg/day mg/day as TID dosing Drowsiness, nausea, dizziness, unsteadiness Level B evidence Topiramate Anticonvulsant with mixed mechanisms of action 25 mg/day mg/day as QHS to BID dosing Paresthesias, weight loss, taste peversion, fatigue, nausea, sedation Level B evidence Alprazolam Benzodiazepine 0.75 mg/day mg/day as BID dosing Sedation, fatigue Level B evidence - recommended with caution due to its abuse potential Botulinum toxin Neuromuscular junction blockade Focal weakness Level C evidence - in medically refractory cases for limb, head and voice tremor Deep brain stimulation Chronic stimulation of VIM nucleus in the thalamus Surgery, finite battery life, foreign body Level B evidence 3,4-DAP; azetazolamide; levetiracetam; methazolamide; mirtazapine; nifedipine; verapamil - are not recommended for the treatment of essential tremor
6 PARKINSON S DISEASE AND OTHER NEURODEGENERATIVE PARKINSONIAN DISORDERS Movement Disorders in the Elderly 6 Parkinson s Disease (PD) Dementia with Lewy Bodies (DLB) Multiple System Atrophy (MSA-C & MSA-P) Progressive Supranuclear Palsy (PSP) Corticobasal Degeneration (CBD) Pathology Parkinsonian Features Synucleinopathies Tauopathies Tremor + +/ Rigidity + (limb) + (limb) + (limb) + (axial>>limb) + (limb, very asymmetric) Akinesia Postural Instability Bradyphrenia Response to Levodopa /- +/ / / Hallmark Features REM sleep behaviour disorder (RBD) Autonomic disturbance (late) Dysphagia (late) Dementia with spontaneous visual hallucinations and fluctuations RBD Autonomic disturbance (late) Dysphagia (late) RBD Early autonomic dysfunction (orthostatic hypotension, postprandial hypotension, anhidrosis with thermoregulatory disturbances, constipation, impotence, poor lacrimation and salivation) Urinary incontinence (early) Cerebellar findings (ataxia, kinetic tremor) - MSA-C Nocturnal stridor NO DEMENTIA Marked postural instability cause early falls Vertical ocular gaze paresis Slow saccades Applause sign (clapping after the patient has been instructed to clap 3 times) Ideomotor apraxia Alien limb Marked asymmetry of signs Cortical sensory loss Progressive aphasia (non-fluent primary progressive aphasia presentation)
7 Pharmacologic treatment of Parkinson s Disease in the Elderly (see additional comments) Early Disease Stage Pharmacologic strategies of symptoms as disease progresses Movement Disorders in the Elderly 7 Dopamine Replacement Motor fluctuations (wearing off) - extend dopamine in brain Dyskinesias - smooth out fluctuation in dopamine levels Autonomic Dysfunction Sleep disorder Cognition & Psychosis Levodopa & Carbidopa 25/100 format - 1/2 tablet PO TID 1hour before meals increase weekly by 1/2 tab TID until reach 2 tabs TID or if symptoms are relieved Dopamine agonists ropinirole* Week mg TID Week 2-0.5mg TID Week mg TID Week 4-1.0mg TID pramipexole* Week mg TID Week mg TID Week 3-0.5mg TID Week mg TID Week 5-1.0mg TID Week mg TID Week 7-1.5mg TID *titrate to symptom relief Levodopa & Carbidopa Increase levodopa dose per time OR increase frequency of levodopa until off-time eliminated Monoamine Oxidase Inhibitor - type B selegiline 5mg qam; max 10mg qd rasagiline COMT-Inhibitor entacapone 200mg PO with each levodopa dose (max 1600 mg/day or 8 times a day) Deep brain stimulation Levodopa & Carbidopa Switch to immediate release levodopa/ carbidopa (not CR) to allow for finer titration, better predictability of medication response, and increase frequency of administration COMT-Inhibitor entacapone 200mg PO with each levodopa dose (max 1600 mg/day or 8 times a day) Amantadine mg qd in divided doses Deep brain stimulation Orthostatic hypotension midodrine 5mg TID (before arising in AM, before lunch, and midafternoon) to start; may need to increase to 10mg TID; do NOT administer after midafternoon to prevent nocturnal supine hypertension; skip dose if BP>180/100 mg Hg in either sitting or supine position fludrocortisone mg/day, can increase to mg/day - contraindicated in CHF and chronic renal failure Erectile dysfunction sildenafil 50mg Constipation polyethylene glycol REM sleep Behaviour Disorder (RBD) melatonin 1 capsule (3 or 5mg) qhs and increase by 1 capsule q2weeks if no change in RBD until maximum of 4 capsules clonazepam 0.5mg to 1mg qhs Excessive daytime somnolence modafanil mg daily Dementia - Acetylcholinesterase inhibitors donepezil 5mg qam with food x 1 month then 10mg qam rivastigmine 1.5mg BID with food then increase by 1.5mg BID every month until reach 6.0mg BID Psychosis Clinical judgmentassess if need to treat psychosis (pleasant nonthreatening hallucinations need NOT be treated) Atypical antipsychotics quetiapine 25mg qhs and increase to 50mg qhs if necessary clozapine
8 Comments Dopamine Replacement Motor fluctuations (wearing off) - extend dopamine in brain Dyskinesias Movement Disorders in the Elderly 8 Psychosis Levodopa & Carbidopa development of motor fluctuations (wearing off phenomenon) & dyskinesias in the long term better to use in the elderly and those with cognitive impairment side-effects include nausea (alleviate by adding extra carbidopa or starting domperidone), dizziness, headache, confusion, delusions, agitation, hallucinations, psychosis Monoamine Oxidase Inhibitor - type B can be use an monotherapy early in the disease process (rasagiline) can be used in conjunction with levodopa (selegiline) side-effects include nausea, headaches, dizziness Amantadine renal excretion (beware of renal failure/elevated creatinine) side-effects include hallucinations and confusions, thus do not use in patients with cognitive impairment acute withdrawal of amantadine can cause an acute delirium and neuroleptic malignant syndrome Atypical antipsychotics clozapine - agranulocytosis Dopamine agonists better to use in younger patients (<65 years) to prevent long-term complications of motor fluctuations and dyskinesias in elderly, more prone to the side effects of hallucinations side-effects hypersomnolence/sleep attacks, hallucinations, nausea, orthostatic hypotension, edema, impulse control disorders (pathologic gambling, shopping and sex)
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationDifferential Diagnosis of Hypokinetic Movement Disorders
Differential Diagnosis of Hypokinetic Movement Disorders Dr Donald Grosset Consultant Neurologist - Honorary Professor Institute of Neurological Sciences - Glasgow University Hypokinetic Parkinson's Disease
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationTremor 101. Objectives 9/30/2015. Importance of tremors
Tremor 101 Umer Akbar, MD Assistant Professor, Brown University Movement Disorders Program, Rhode Island Hospital & Butler Hospital Objectives Recognize and describe the qualities of common types of tremor
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationMovement Disorders- Parkinson s Disease. Fahed Saada, MD March 8 th, th Family Medicine Refresher Course St.
Movement Disorders- Parkinson s Disease Fahed Saada, MD March 8 th, 2019 48 th Family Medicine Refresher Course St. Joseph s Health Disclosure ACADIA Pharmaceuticals Objectives Review the classification
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationTremor What is tremor? What causes tremor? What are the characteristics of tremor? What are the different categories of tremor?
Tremor What is tremor? Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. It is the most common of all involuntary
More informationApproach to Tremor in Older Adults
Neurology Primer Approach to Tremor in Older Adults Joel S. Hurwitz, MB, FRCPC, FRCP (London), Associate Professor, Department of Medicine (Division of Geriatric Medicine), University of Western Ontario,
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationDisorders of Movement M A R T I N H A R L E Y N E U R O L O G Y
Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y Educational Objectives Improved history taking in patients with movement disorders. Develop a systematic approach to observing and describing
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationDate of Referral: Enhanced Primary Care Pathway: Parkinson s Disease
Specialist LINK Linking Physicians CALGARY AND AREA Patient Name: Date of Birth: Calgary RHRN: PHN / ULI: Date of Referral: Referring MD: Fax: Today s Date: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS:
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationAtypical parkinsonism
Atypical parkinsonism Wassilios Meissner Service de neurologie et CMR atrophie multisystématisée, CHU de Bordeaux Institut des Maladies Neurodégénératives, Université Bordeaux 2, CNRS UMR 5293 Parkinsonism?
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More information2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor
Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease
More informationParkinson s Disease and other related movement disorders a video guide to diagnosis
Parkinson s Disease and other related movement disorders a video guide to diagnosis Parkinson s Disease Masterclass November 2017 Dr Frank Phelan MidYorkshire Hospitals NHS Trust Ideopathic Parkinson s
More informationSTEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS)
STEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS) Karen M. Thomas D.O. Diplomate, ABPN Director of Movement Disorders Program Director of Comprehensive Parkinson s Disease Program Sentara
More informationParts of the motor circuits
MOVEMENT DISORDERS Parts of the motor circuits cortical centers: there are centers in all the cortical lobes subcortical centers: caudate nucleus putamen pallidum subthalamical nucleus (Luys) nucleus ruber
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationMovement Disorders. Eric Kraus, MD! Neurology!
Movement Disorders Eric Kraus, MD! Neurology! Classify Bradykinesia! Tic! Myoclonus! Tremor! Dystonia! Athetosis! Chorea! Ballismus! Case 1 This 64 year-old female has had progression of a tremor over
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE
ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE The Basal Ganglia Primary motor cortex Execution of movement
More informationMOVEMENT DISORDERS UPDATE H. MURRAY TODD, M.D., F.A.A.N.
MOVEMENT DISORDERS UPDATE H. MURRAY TODD, M.D., F.A.A.N. Movement Disorders Hypokinesia : decreased voluntary and automatic movements Hyperkinesia : excessive movements HYPOKINESIAS Parkinson s disease
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationObjectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures
12:45 1:30 pm PD or not PD? Distinguishing Parkinson s Disease From Other Parkinsonian and Tremor Syndromes SPEAKER Jennifer G. Goldman, MD, MS Presenter Disclosure Information The following relationships
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationJoint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD
Joint Session with ACOFP and Mayo Clinic Parkinson's Disease: 5 Pearls Jay Van Gerpen, MD Parkinson s Disease: 5 Pearls J.A. van Gerpen, MD Sections of Movement Disorders and Clinical Neurophysiology
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationDepression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS
Depression & Anxiety One set of important protectors from depression is friends and family as much as you can, keep yourself active and engaged with others. Exercise, particularly while outside, may help.
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationM. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment
M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz Parkinson s Disease A Guide to Medical Treatment SEEd srl. All rights reserved Piazza Carlo Emanuele II, 19 10123 Torino, Italy Tel. 011.566.02.58
More informationHyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom
Hyperkinetic Movement Disorders Sarah Furtado, MD, PhD, FRCPC James case A mother brings her son James, 10, to your office because of repetitive sniffing sounds and repetitive eye blinking. This sniffing
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More informationSection Editor Howard I Hurtig, MD
1 of 5 9/29/2013 6:56 PM Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis,
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationPresented by Joanna O Leary, MD Providence St. Vincent Medical Center Movement Disorder Department
Presented by Joanna O Leary, MD Providence St. Vincent Medical Center Movement Disorder Department Hyperkinetic movement disorders Increase in muscle movements causing involuntary motion Tremor Dystonia
More informationCONTRIBUTORS The American Academy of Neurology Institute.
Several of these multiple-choice questions were originally published in Continuum: Lifelong Learning in Neurology Movement Disorders, Volume 22, Issue 4, August 2016 based on the content in the issue developed
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called
More informationUnderstanding Tremor Diagnosis, Cause, Treatment. Monique Giroux, MD Englewood and Fort Collins, CO
Understanding Tremor Diagnosis, Cause, Treatment Monique Giroux, MD Englewood and Fort Collins, CO What is Tremor? Involuntary Rhythmic and Oscillatory Produced by contraction of alternating muscles Types
More informationTremor, Rigidity, Tics and Dystonia: The 4 Most Common Movement Disorders
Tremor, Rigidity, Tics and Dystonia: The 4 Most Common Movement Disorders VIGNETTE 1: HAND SHAKING 62 YOF tremor of both hands for 6 years FHx: Shaking in mother & maternal cousin PMH: Depression, HTN,
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationDrugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationEvolution of a concept: Apraxia/higher level gait disorder. ataxia v. apraxia gait = limb apraxia. low, middle, high gait disturbance levels
Case #1 81-year-old woman Gait Imbalance: Two Unusual Cases in Older Patients February 2008: 3 years of gradually progressive gait imbalance no vertigo, dizziness or paresthesias etiology unclear on examination
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationWith Time, The Pathology of PD Spreads Throughout the Brain
With Time, The Pathology of PD Spreads Throughout the Brain Braak s staging of Parkinson s disease pathology dm co sn mc hc fc 1 Hubert H. Fernandez, MD, FAAN Professor of Medicine (Neurology) Cleveland
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationIssues for Patient Discussion
onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing
More informationMovement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types
Background Movement Disorders Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Early Studies Found some patients with progressive weakness
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationAn Approach to Patients with Movement Disorders
An Approach to Patients with Movement Disorders Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon EDUCATIONAL TOOLS MDS video library
More informationUpdate on the Treatment of Parkinson s Disease. Neurotherapeutics for Rehab Professionals November 6 th, 2015
Brent Bluett, DO Dr. Brent Bluett completed medical school at Touro Unviersity Nevada College of Osteopathic Medicine, neurology residency at the University of Texas Southwestern at Austin, and a Movement
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationParkinson s Disease and Treatment Options for the Younger Adult
Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had Tremor of her right hand
More informationParkinson s Disease and Treatment Options for the Younger Adult
The Way CME Should Be Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had
More informationCanadian Guidelines on Parkinson s Disease Executive Summary
Canadian Guidelines on Parkinson s Disease Executive Summary Re: Can J Neurol Sci. 2012;39: Suppl 4: S1-S30 The aim of the Canadian Guidelines on Parkinson s Disease is to enhance the care for all Canadians
More informationThe Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia
Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME
More informationDeep Brain Stimulation: Indications and Ethical Applications
Deep Brain Stimulation Overview Kara D. Beasley, DO, MBe, FACOS Boulder Neurosurgical and Spine Associates (303) 562-1372 Deep Brain Stimulation: Indications and Ethical Applications Instrument of Change
More informationExtrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010
Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate
More informationUnderstanding Parkinson s Disease Important information for you and your loved ones
Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson
More informationSubthalamic Nucleus Deep Brain Stimulation (STN-DBS)
Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) A Neurosurgical Treatment for Parkinson s Disease Parkinson s Disease Parkinson s disease is a common neurodegenerative disorder that affects about
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationNon-Motor Symptoms of Parkinson s Disease
Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More information